美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

GSK plc ADRhedged

67.19

+0.89981.36%

成交量：3

成交额：199

市值：67.19万

市盈率：- -

高：67.19

开：66.29

低：67.19

收：66.29

52周最高：85.03

52周最低：61.00

股本：1.00万

流通股本：1.00万

量比：0.01

换手率：0.03%

股息：2.08

股息率：3.09%

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

司美格鲁肽专利悬崖在前诺和诺德如何只靠新产品完成1500亿丹麦克朗销售目标？

每日经济新闻

科创板集成电路、创新药研发成果进入实质兑现期

中国经营报

据报道，Summit Therapeutics（SMMT）周一表示，英国制药公司阿斯利康（AstraZeneca，AZN

公告精选︱科达制造：拟投资约45亿元建设年产50万吨石墨负极材料一体化项目；百花医药：不涉及创新药研发

创新药热度飙升，关注100%创新药研发标的

全球药企“抢滩”中国管线：从成本嫁接走向早期合作

葛兰素史克（GSK）拟斥资7.5亿美元收购Chimagen旗下TCE项目全球独家权益

118款生物药专利悬崖将至，中国药企业迎战MNC最大专利悬崖

乙肝新药中国数据出炉，但实现患者的“治愈梦”仍有门槛

每日经济新闻

功能性治愈率最高61%！乙肝新药中国数据出炉但7500万患者的“治愈梦”仍有门槛

每日经济新闻

总额可达12.95亿美元！和黄全球首创偶联药物出海

和黄医药午后飙升逾16%，与葛兰素史克达成最高12.95亿美元肿瘤药授权合作

老虎资讯综合

药闻 | 英硅智能上市后首份半年报扭亏创新药研发加速拥抱AI

联环药业上半年扭亏为盈集采续采与创新药研发协同推进

能够治愈乙肝的新药来了？专家：距离攻克乙肝仍有差距，但临床多了一件新武器

每日经济新闻

葛兰素史克(GSK)拟发行至少20亿欧元债券，以偿还并购融资贷款。

博济医药2026年半年报：创新药研发需求复苏，在手订单充足，经营现金流明显下滑

GSK：NUCALA获加拿大药品管理局积极报销推荐，用于成人慢性阻塞性肺疾病治疗。

中外制药与葛兰素史克签署抗登革热病毒抗体“AID351”独家许可协议

中外制药与葛兰素史克达成协议，共同推进登革热抗体药物开发

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/GSKH/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GSKH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","market":"US","secType":"STK","nameCN":"GSK plc ADRhedged","latestPrice":67.1856,"timestamp":1791835200000,"preClose":66.2858,"halted":0,"volume":3,"delay":0,"changeRate":0.013574551412217988,"floatShares":10001,"shares":10001,"eps":0,"marketStatus":"盘前交易","change":0.8998,"latestTime":"10-13 04:16:54 EDT","open":66.2858,"high":67.1856,"low":67.1856,"amount":199,"amplitude":0,"askPrice":106.82,"askSize":100,"bidPrice":27.01,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791898200000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":67.1856,"nav":66.281474,"aum":662881.021474,"dividendRate":0.030899,"bidAskSpread":0,"volumeRatio":0.010482182491023583,"impliedVol":0.3657,"impliedVolPercentile":0.9925},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","floatShares":10001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.010482182491023583,"shares":10001,"dividePrice":2.076,"high":67.1856,"amplitude":0,"preClose":66.2858,"low":67.1856,"week52Low":61,"pbRate":"--","week52High":85.03,"institutionHeld":0,"latestPrice":67.1856,"eps":0,"divideRate":0.030899,"volume":3,"delay":0,"ttmEps":0,"open":66.2858,"prevYearClose":68.2031,"prevWeekClose":66.2858,"prevMonthClose":68.5811,"prevQuarterClose":68.5811,"fiveDayClose":66.3846,"twentyDayClose":69.8025,"sixtyDayClose":71.9041},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GSKH\",params:#limit:5,,,undefined,":[{"date":"2026-06-16","symbol":"GSKH","amount":0.92785,"announcedDate":"2026-06-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-16","defaultRemindTime":1781616600000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-23","payableDate":"2026-06-16","currency":"USD","dateTimestamp":1781582400000,"payDate":"2026-06-23"},{"date":"2026-03-16","symbol":"GSKH","amount":0.36332,"announcedDate":"2026-03-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-16","defaultRemindTime":1773667800000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-23","payableDate":"2026-03-16","currency":"USD","dateTimestamp":1773633600000,"payDate":"2026-03-23"},{"date":"2025-12-16","symbol":"GSKH","amount":0.78682,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GSKH\",market:\"US\",,,undefined,":[{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.78682,"currency":"USD"},{"executeDate":"2026-03-16","recordDate":"2026-03-16","paymentDate":"2026-03-23","value":0.36332,"currency":"USD"},{"executeDate":"2026-06-16","recordDate":"2026-06-16","paymentDate":"2026-06-23","value":0.92785,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GSKH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GSKH\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673602556","title":"司美格鲁肽专利悬崖在前 诺和诺德如何只靠新产品完成1500亿丹麦克朗销售目标？","url":"https://stock-news.laohu8.com/highlight/detail?id=2673602556","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673602556?lang=zh_cn&edition=fundamental","pubTime":"2026-10-08 14:07","pubTimestamp":1791439654,"startTime":"0","endTime":"0","summary":"近日，诺和诺德召开全球媒体沟通会。诺和诺德公司全球总裁兼CEO杜麦克（MikeDoustdar）、首席科学官MartinHolstLange、产品与产品组合战略全球执行副总裁周虹及国际运营部执行副总裁林意明（EmilKongshjLarsen）等集体出席，围绕核心分子司美格鲁肽的战略定位、口服制剂的全球部署以及管线与并购的推进逻辑，作出系统阐述。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610083889529730.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610083889529730.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IYH","TRUH","BBH","BGIA","MEDI","RSPH","FXH","BME","GSKH","PBPH","JDOC","BBP","PJP","IHE","PPH","FHLC","APXH","TMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673501811","title":"科创板集成电路、创新药研发成果进入实质兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2673501811","media":"中国经营报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673501811?lang=zh_cn&edition=fundamental","pubTime":"2026-10-07 19:56","pubTimestamp":1791374163,"startTime":"0","endTime":"0","summary":"近期，科创板公司研发频传利好消息，从创新药的首例入组和新适应证获批，到集成电路的存储平台量产与核心芯片交付，越来越多成果转化为实实在在的创新产出，科创板硬科技企业正从“持续投入”走向“成果兑现”。集成电路板块多点突破，存储、端侧AI、模拟与车规芯片均有实质进展落地。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610073888922323.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610073888922323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BBP","PBE","KSTR","WRND","BIOY","LFSC","XLVI","BK4585","BK4588","IBB","GDOC","APXH","159546","GSKH","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671265237","title":"据报道，Summit Therapeutics（SMMT）周一表示，英国制药公司阿斯利康（AstraZeneca，AZN","url":"https://stock-news.laohu8.com/highlight/detail?id=2671265237","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671265237?lang=zh_cn&edition=fundamental","pubTime":"2026-09-29 07:52","pubTimestamp":1790639529,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4539","BK4007","LENZ","GSKH","BK4139","LU2488822045.USD","SMMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669169682","title":"公告精选︱科达制造：拟投资约45亿元建设年产50万吨石墨负极材料一体化项目；百花医药：不涉及创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2669169682","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669169682?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 21:52","pubTimestamp":1789998737,"startTime":"0","endTime":"0","summary":"逸豪新材：拟定增募资不超过18亿元用于增资收购铭丰电子不低于78%股权","market":"us","thumbnail":"https://img7.gelonghui.com/column/2/111.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/111.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/6758003","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK0102","BIOY","BK4585","BK0070","PBE","GSKH","IBB","BK0251","WRND","BK0155","GDOC","BBP","600499","BK0188","BK4588","600721","BK0216","XLVI","SETM","LFSC","APXH","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669137049","title":"创新药热度飙升，关注100%创新药研发标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2669137049","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669137049?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 13:55","pubTimestamp":1789970100,"startTime":"0","endTime":"0","summary":"MACD金叉信号形成，这些股涨势不错！","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-21/doc-inisqkzy8876594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SBIO","IBBQ","GDOC","WRND","GSKH","BIOY","LFSC","APXH","XLVI","IBB","MEDX","BK1161","BK4585","159992","06978","BK4588","BBP","LNGR","BK1574","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668694451","title":"全球药企“抢滩”中国管线：从成本嫁接走向早期合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2668694451","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668694451?lang=zh_cn&edition=fundamental","pubTime":"2026-09-18 17:14","pubTimestamp":1789722892,"startTime":"0","endTime":"0","summary":"从“产品出海”到“生态融合”，中国生物医药的全球化合作出现新的变化。国家药监局数据显示，2026年1—6月，中国创新药对外授权交易共81笔，总额约1100亿美元，已达2025年全年总额的八成，创历史新高。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609183878667977.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609183878667977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4007","BK4585","BK4588","BK4532","GSK","GSKH","GSK.UK","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667637649","title":"葛兰素史克（GSK）拟斥资7.5亿美元收购Chimagen旗下TCE项目全球独家权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2667637649","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667637649?lang=zh_cn&edition=fundamental","pubTime":"2026-09-15 18:32","pubTimestamp":1789468371,"startTime":"0","endTime":"0","summary":"金吾财讯 | 葛兰素史克（GSK）已与Chimagen Biosciences达成协议，将以高达7.5亿美元的交易总额，收购后者一款用于治疗多发性骨髓瘤的三特异性T细胞衔接器（TCE）项目的全球独家权益。根据协议，GSK将向Chimagen支付一笔首付款，并根据后续研发与商业化进展支付相应的里程碑付款。该候选药物能够同时靶向T细胞及两种肿瘤相关抗原，目前预计将于2027年正式进入I期临床试验阶段。此前，双方已就另一款处于I期临床、针对CD19/CD20的双重TCE药物CMG1A46达成合作，本次交易标志着GSK在多发性骨髓瘤及血液瘤产品线上的进一步深化布局。","market":"other","thumbnail":"https://static.szfiu.com/news/20250107/ODI2NGE1NjlmODgxZDI1NzFmMmQ4ODQzNDA1OTI5NjU2Mg==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ODI2NGE1NjlmODgxZDI1NzFmMmQ4ODQzNDA1OTI5NjU2Mg==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"306052","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4588","GSK","GSKH","BK4007","BK4585","GSK.UK","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666563124","title":"118款生物药专利悬崖将至，中国药企业迎战MNC最大专利悬崖","url":"https://stock-news.laohu8.com/highlight/detail?id=2666563124","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666563124?lang=zh_cn&edition=fundamental","pubTime":"2026-09-10 15:26","pubTimestamp":1789025185,"startTime":"0","endTime":"0","summary":"BCG合伙人杜菁博士指出，未来几年全球MNC将迎来史上最大专利悬崖，有118种生物制剂将会失去相应的专利保护，涉及2340亿美元市场。然而，目前这118款即将到期分子中，只有极少数在火热开发，大量缺口有待生物类似药填补。目前来说，创新药出海还没办法完成这个闭环，但生物类似药作为先头部队做出海试验，企业风险和获益会更高。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789025064363150858","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["FHLC","159839","BBP","MEDI","GSKH","JDOC","IYH","PBPH","APXH","PJP","RSPH","IHE","TMED","TRUH","FXH","PPH","BBH","BME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665937331","title":"乙肝新药中国数据出炉，但实现患者的“治愈梦”仍有门槛","url":"https://stock-news.laohu8.com/highlight/detail?id=2665937331","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665937331?lang=zh_cn&edition=fundamental","pubTime":"2026-09-08 20:51","pubTimestamp":1788871868,"startTime":"0","endTime":"0","summary":"中国慢性乙型肝炎（以下简称慢乙肝）患者的“治愈”故事，正在萌芽。日前，在新加坡召开的亚洲肝病学峰会暨乙肝病毒治愈科学会议上，反义寡核苷酸（ASO）药物Bepirovirsen全球Ⅲ期研究（BWell研究）的中国人群数据完成了全球首秀：中国慢乙肝患者功能性治愈率最高可达61%，疗效与安全性趋势与全球数据一致。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609083868286383.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609083868286383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","BK4561","BK4532","BK4200","BK4588","LU1829250122.USD","GSK.UK","GSKH","ASO","BK4007","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665535012","title":"功能性治愈率最高61%！乙肝新药中国数据出炉 但7500万患者的“治愈梦”仍有门槛","url":"https://stock-news.laohu8.com/highlight/detail?id=2665535012","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665535012?lang=zh_cn&edition=fundamental","pubTime":"2026-09-05 12:14","pubTimestamp":1788581677,"startTime":"0","endTime":"0","summary":"【功能性治愈率最高61%！乙肝新药中国数据出炉 但7500万患者的“治愈梦”仍有门槛】8月31日—9月5日，在新加坡召开的亚洲肝病学峰会（AHS）暨HBV（乙型肝炎病毒）治愈科学会议上，反义寡核苷酸（ASO）药物Bepirovirsen全球Ⅲ期研究（B-Well研究）的中国人群数据完成了全球首秀：中国慢乙肝患者功能性治愈率最高可达61%，疗效与安全性趋势与全球数据一致。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609053865995314.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609053865995314.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1223082519.USD","BK4532","LU1223082196.USD","SGDM","BK4017","BK4599","BK4561","BK4007","XME","BK4585","LU1829250122.USD","LU1878469433.USD","ALT","GSK","BK4588","ASO","BK4200","SIL","GSK.UK","BK4139","LU1223083913.SGD","CHB","GSKH","CDE","GDXJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664960827","title":"总额可达12.95亿美元！和黄全球首创偶联药物出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2664960827","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664960827?lang=zh_cn&edition=fundamental","pubTime":"2026-09-03 16:03","pubTimestamp":1788422625,"startTime":"0","endTime":"0","summary":"9月3日，和黄医药（00013.HK）宣布旗下子公司和记黄埔与葛兰素史克（GSK）附属公司达成独家开发及许可协议，授予后者除中国大陆、香港、澳门和台湾以外的全球范围内开发和商业化HMPL-A830的权利。临床开发将首先聚焦于结直肠癌、胰腺癌和肺癌适应症。协议包括1.1亿美元的首付款以及潜在的开发、注册和商业化里程碑付款，总额可达12.95亿美元，外加基于净销售额的特许权使用费。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609033864044420.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609033864044420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1587","GSK","BK1191","00013","BK4585","BK4007","BK4588","GSKH","GSK.UK","LU1829250122.USD","BK4532","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124565155","title":"和黄医药午后飙升逾16%，与葛兰素史克达成最高12.95亿美元肿瘤药授权合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1124565155","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124565155?lang=zh_cn&edition=fundamental","pubTime":"2026-09-03 15:56","pubTimestamp":1788422188,"startTime":"0","endTime":"0","summary":"$和黄医药(00013)$周四午后股价大幅走高，一度升逾16%，势创2022年11月以来最大单日升幅。消息面上，和黄医药周四宣布，旗下公司与$葛兰素史克(GSK)$附属公司签署独家开发及许可协议，双方将合作开发及商业化在研肿瘤药物HMPL-A830。根据协议，和黄医药将获得1.1亿美元首付款，并有权获得最高12.95亿美元的开发、监管及商业化里程碑付款，以及产品上市后的净销售额特许权使用费。受大额授权合作消息刺激，和黄医药午后获资金明显追捧，股价升幅迅速扩大。","market":"hk","thumbnail":"https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013","GSKH","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663282078","title":"药闻 | 英硅智能上市后首份半年报扭亏 创新药研发加速拥抱AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2663282078","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663282078?lang=zh_cn&edition=fundamental","pubTime":"2026-08-31 15:35","pubTimestamp":1788161758,"startTime":"0","endTime":"0","summary":"新华财经上海8月31日电（记者杜康）作为AI制药领域代表性企业之一，英硅智能（03696.HK）日前发布2026年度中期业绩报告。上半年，公司实现总营收1.063亿美元，同比增长287.2%；净利润3554万美元，经调整净利润5123万美元，经营活动现金流转正。这是英硅智能上市后发布的首份半年报，公司也由此前的亏损转为盈利。从收入结构看，药物研发与管线开发仍是主要来源。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608313860072952.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608313860072952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBB","IPOS","SBIO","BBP","XLVI","ARTY","PBE","AGIX","BK4585","AIPO","QTOC","VTHR","BIOY","LFSC","CHAT","BK4588","GSKH","WRND","GDOC","APXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663044177","title":"联环药业上半年扭亏为盈 集采续采与创新药研发协同推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2663044177","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663044177?lang=zh_cn&edition=fundamental","pubTime":"2026-08-30 21:12","pubTimestamp":1788095520,"startTime":"0","endTime":"0","summary":"业绩实现扭亏为盈经营基本面持续改善今年上半年，联环药业经营业绩实现明显改善。对此，联环药业正持续推进相关工作。值得注意的是，联环药业已经开始围绕创新药商业化进行营销体系布局。除LH-1801外，联环药业产品注册申报也取得阶段性进展。从核心产品稳定销售，到集采品种持续放量，再到创新药研发向上市申报环节推进，联环药业正在逐步形成多层次的业务增长支撑。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","APXH","LFSC","BK0239","WRND","BIOY","BK4585","GDOC","SBIO","XLVI","PBE","GSKH","IBB","BBP","600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662606708","title":"能够治愈乙肝的新药来了？专家：距离攻克乙肝仍有差距，但临床多了一件新武器","url":"https://stock-news.laohu8.com/highlight/detail?id=2662606708","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662606708?lang=zh_cn&edition=fundamental","pubTime":"2026-08-28 19:15","pubTimestamp":1787915749,"startTime":"0","endTime":"0","summary":"乙肝治疗领域迎来历史性突破。近日，葛兰素史克（GSK）宣布，其反义寡核苷酸（ASO）药物贝普若韦生（Bepirovirsen）已在日本获批上市，用于治疗既往接受过至少6个月核苷（酸）类似物治疗且符合预先设定的病毒学指标的成年慢性乙型肝炎（CHB）病毒感染患者，以达到功能性治愈的目的。据悉，这是Bepirovirsen在全球范围内的首次获批。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608283858475454.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608283858475454.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","BK4561","GDXJ","XME","CAM","GSK.UK","GSKH","BK4200","BK4585","GSK","LU1829250122.USD","LU1223083913.SGD","SGDM","BK4017","CHB","SIL","BK4007","LU1223082519.USD","CDE","LU1223082196.USD","BK4532","IBBQ","ASO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662081157","title":"葛兰素史克(GSK)拟发行至少20亿欧元债券，以偿还并购融资贷款。","url":"https://stock-news.laohu8.com/highlight/detail?id=2662081157","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662081157?lang=zh_cn&edition=fundamental","pubTime":"2026-08-27 18:00","pubTimestamp":1787824828,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4588","BUYO","NBIE","FYLG","GSK.UK","GSKH","MRGR","BK4585","LBO","GSK","LU1829250122.USD","RSPF","TFNS","LQPE","BK4007","ARB","BNDW","PEX","BK4532","FXE","MNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662752987","title":"博济医药2026年半年报：创新药研发需求复苏，在手订单充足，经营现金流明显下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2662752987","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662752987?lang=zh_cn&edition=fundamental","pubTime":"2026-08-27 14:57","pubTimestamp":1787813849,"startTime":"0","endTime":"0","summary":"然而，需警惕新药研发政策变化、项目执行延期及市场竞争加剧带来的风险，同时关注经营现金流与净利润背离的情况。后续需重点关注公司在手订单转化进度、临床前及临床研究服务的毛利率变化趋势，以及经营现金流的改善情况。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787797151251328663","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["SBIO","SPHQ","BK4585","159399","BK4588","BBP","BK0216","APXH","BIOY","WRND","XLVI","LFSC","PBE","IBB","300404","GDOC","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660493380","title":"GSK：NUCALA获加拿大药品管理局积极报销推荐，用于成人慢性阻塞性肺疾病治疗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2660493380","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660493380?lang=zh_cn&edition=fundamental","pubTime":"2026-08-18 22:23","pubTimestamp":1787062997,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","GSK.UK","GSKH","BK4532","BK4585","BK4007","GSK","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660456776","title":"中外制药与葛兰素史克签署抗登革热病毒抗体“AID351”独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2660456776","media":"第一财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660456776?lang=zh_cn&edition=fundamental","pubTime":"2026-08-18 10:49","pubTimestamp":1787021377,"startTime":"0","endTime":"0","summary":"【中外制药与葛兰素史克签署抗登革热病毒抗体“AID351”独家许可协议】据中外制药官网消息，8月18日，中外制药宣布已与葛兰素史克签署独家许可协议，葛兰素史克将获得抗登革热病毒抗体药物“AID351”的全球独家开发、生产和商业化权利，并负责该药物的临床开发及生产。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608183844335660.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608183844335660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","GSKH","01477","LU1829250122.USD","BK4532","BK4588","GSK","BK4007","GSK.UK","BK1574","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660456160","title":"中外制药与葛兰素史克达成协议，共同推进登革热抗体药物开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2660456160","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660456160?lang=zh_cn&edition=fundamental","pubTime":"2026-08-18 10:38","pubTimestamp":1787020681,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1829250122.USD","BK4532","BK4588","BK4007","GSKH","GSK.UK","GSK","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":91,"code":"91000000","status":"200"}]}}